ReviewJournal of nanobiotechnology2021
Nanomaterials and hepatic disease: toxicokinetics, disease types, intrinsic mechanisms, liver susceptibility, and influencing factors.
Review in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Analyzing Molecular Determinants of Nanodrugs' Cytotoxic Effects.International journal of molecular sciences · 2025Pooled it
- Liver fibrosis: Pathogenesis and innovative nanoparticle-based therapeutic strategies.International journal of pharmaceutics: X · 2026Review
- Nanoparticle approaches for hepatitis therapy and clinical translation.Discover nano · 2026Review
- Nanotechnology-Enabled Diagnosis and Treatment of Hepatocellular Carcinoma: Theranostics, Combination Regimens, and Translation.International journal of nanomedicine · 2026Review
- Nanotechnology for atherosclerotic plaque stabilisation: bridging innovation and clinical practice.EBioMedicine · 2026Review
- RNA Sequencing Explores Potential Mechanisms Underlying the Enhanced Aggressive Phenotype of HepG2 Cells Induced by Aged Zinc Oxide Nanoparticles.International journal of nanomedicine · 2026Article
- Hepatoprotection by Naringin Nanoliposomes Against Nickel Toxicity Involves Antioxidant Reinforcement and Modulation of Nrf2, NF-κB, PI3K/mTOR, JAK/STAT, and Apoptotic Pathways.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Development of Immune-Regulatory Pseudo-Protein-Coated Iron Oxide Nanoparticles for Enhanced Treatment of Triple-Negative Breast Tumor.Nanomaterials (Basel, Switzerland) · 2025Article
- Cuproptosis Cell Death Molecular Events and Pathways to Liver Disease.Journal of inflammation research · 2025Review
- Black phosphorus for bone regeneration: Mechanisms involved and influencing factors.Materials today. Bio · 2024Review
- Anti-inflammatory and anti-angiogenic effects ofJournal of medicine and life · 2024Article
- Emerging Role of Extracellular Vesicles in Intercellular Communication in the Brain: Implications for Neurodegenerative Diseases and Therapeutics.Cell biochemistry and biophysics · 2024Review
- Multifaceted Characterization for the Hepatic Clearance of Graphene Oxide and Size-Related Hepatic Toxicity.Molecules (Basel, Switzerland) · 2024Article
- Iron oxide nanoparticles trigger endoplasmic reticulum damage in steatotic hepatic cells.Nanoscale advances · 2023Article
- Frontiers in hepatic drug delivery-grand challenges.Frontiers in drug delivery · 2023Article
- Crocin averts functional and structural rat hepatic disturbances induced by copper oxide nanoparticles.Toxicology research · 2022Article
- Biodistribution Profile of Magnetic Nanoparticles in Cirrhosis-Associated Hepatocarcinogenesis in Rats by AC Biosusceptometry.Pharmaceutics · 2022Article
- Nanomaterials alleviating redox stress in neurological diseases: mechanisms and applications.Journal of nanobiotechnology · 2022Review
- Environmental exposure as a risk-modifying factor in liver diseases: Knowns and unknowns.Acta pharmaceutica Sinica. B · 2021Review
- Nanotherapies for sepsis by regulating inflammatory signals and reactive oxygen and nitrogen species: New insight for treating COVID-19.Redox biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
The widespread use of nanomaterials (NMs) has raised concerns that exposure to them may introduce potential risks to the human body and environment. The liver is the main target organ for NMs. Hepatotoxic effects caused by NMs have been observed in recent studies but have not been linked to liver disease, and the intrinsic mechanisms are poorly elucidated. Additionally, NMs exhibit varied toxicokinetics and induce enhanced toxic effects in susceptible livers; however, thus far, this issue has not been thoroughly reviewed. This review provides an overview of the toxicokinetics of NMs. We highlight the possibility that NMs induce hepatic diseases, including nonalcoholic steatohepatitis (NASH), fibrosis, liver cancer, and metabolic disorders, and explore the underlying intrinsic mechanisms. Additionally, NM toxicokinetics and the potential induced risks in the livers of susceptible individuals, including subjects with liver disease, obese individuals, aging individuals and individuals of both sexes, are summarized. To understand how NM type affect their toxicity, the influences of the physicochemical and morphological (PCM) properties of NMs on their toxicokinetics and toxicity are also explored. This review provides guidance for further toxicological studies on NMs and will be important for the further development of NMs for applications in various fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.